Evidence map›Paper›PMID 36378544›Full record

ArticleJournal of clinical hypertension (Greenwich, Conn.)2022

Impact of sustained hypertension on new cardiovascular events in patients with type 2 diabetes: KAMOGAWA-HBP study.

Takashi Yoshimura, Emi Ushigome, Shinnosuke Hata, Maya Takegami, Goji Hasegawa, Toru Tanaka, Sei Tsunoda, Masayoshi Ohnishi, Isao Yokota, Hidetaka Ushigome and 5 more

Abstract read
In one paragraph

Article in Journal of clinical hypertension (Greenwich, Conn.), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Takashi YoshimuraDepartment of Endocrinology and Metabolism, Graduate School of Medical, Science, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Emi UshigomeDepartment of Endocrinology and Metabolism, Graduate School of Medical, Science, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Shinnosuke HataDepartment of Endocrinology and Metabolism, Graduate School of Medical, Science, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Maya TakegamiDepartment of Endocrinology and Metabolism, Graduate School of Medical, Science, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Goji HasegawaDepartment of Endocrinology and Metabolism, Kyoto Second Red Cross Hospital, Kyoto, Japan.
Toru TanakaDepartment of Endocrinology and Metabolism, Kyoto First Red Cross Hospital, Kyoto, Japan.
Sei TsunodaDepartment of Cardiology, Nishijin Hospital, Kyoto, Japan.
Masayoshi OhnishiDepartment of Endocrinology and Metabolism, Osaka General Hospital of West Japan Railway Company, Osaka, Japan.
Isao YokotaDepartment of Biostatistics, Kyoto Prefectural University, Kyoto, Japan.
Hidetaka UshigomeDepartment of Organ Transplantation and General Surgery, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Nobuko KitagawaDepartment of Endocrinology and Metabolism, Graduate School of Medical, Science, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Mai AsanoDepartment of Endocrinology and Metabolism, Graduate School of Medical, Science, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Masahide HamaguchiDepartment of Endocrinology and Metabolism, Graduate School of Medical, Science, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Masahiro YamazakiDepartment of Endocrinology and Metabolism, Graduate School of Medical, Science, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Michiaki FukuiDepartment of Endocrinology and Metabolism, Graduate School of Medical, Science, Kyoto Prefectural University of Medicine, Kyoto, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We have previously shown that masked hypertension (MH) and sustained hypertension (SH) contribute to the progression of diabetic nephropathy. Although the risk of target organ damage and cardiovascular events in MH and SH is significantly higher than that in normotension and white coat hypertension, the role of MH or SH in cardiovascular events has never been reported in studies specific to diabetic patients. Therefore, in this study, we aimed to determine whether blood pressure control status contributes to the development of new cardiovascular events. A longitudinal study of 1082 patients with type 2 diabetes mellitus and no history of cardiovascular events was conducted. Patients were instructed to have their blood pressure measured three times, every morning and evening, for 14 consecutive days. Hypertension status was classified into four groups based on the systolic blood pressure measurements in the clinic and at home. The primary endpoint was the first cardiovascular event. After a median follow-up of 7.0 (interquartile range, 4.0-9.0) years, 119 patients developed cardiovascular events. The hazard ratio (95% confidence interval) for the risk of developing cardiovascular events was significantly higher in the SH group than in the controlled blood pressure group (1.63 [1.02-2.59]). SH is a useful predictor of cardiovascular events. Both at home and in the clinic, blood pressure monitoring should be assessed in routine clinical practice to predict future cardiovascular events in patients with type 2 diabetes.

Indexed as

Diabetes Mellitus, Type 2HypertensionHumansLongitudinal Studiesnew cardiovascular eventssustained hypertensiontype 2 diabetes

Identifiers

PMID36378544
PMCPMC9731590

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.